Argentina’s National Administration of Drugs, Foods, and Medical Devices (Anmat) has made a significant decision to permanently revoke the operating licenses of HLB Pharma and Laboratorios Ramallo. This action follows the production of contaminated fentanyl, which tragically led to the deaths of at least 111 individuals between late 2024 and the first half of 2025, marking one of the most severe health crises in the nation’s recent history.
Regulatory Action
The formal revocation was enacted through resolution 1848/2026, published in the Official Gazette. This resolution concludes an administrative process initiated in May 2025, which began with Anmat’s suspension of the two companies’ production activities. Furthermore, the agency prohibited the use, distribution, and sale of all products from these laboratories.
Anmat’s rationale for this decision underscores alarming deficiencies in quality control within the companies. The agency concluded that the firms’ practices posed a significant risk to public health, with the potential to cause widespread harm. It emphasized that the situation represented a “critical, significant, and unavoidable risk” to the population’s wellbeing.
Lack of Compliance
Notably, both HLB Pharma and Laboratorios Ramallo failed to provide adequate plans to rectify the identified irregularities. They did not request subsequent inspections nor contest previous sanctions. Additionally, both companies currently lack a responsible technical director. Although product certificates remain active due to ongoing criminal proceedings, the companies will not be allowed to operate.
The Origin of the Crisis
The crisis began when two multidrug-resistant bacteria, including Klebsiella pneumoniae, were found in sealed fentanyl ampoules produced by HLB Pharma. This contamination was directly linked to patients in intensive care units, first detected at the Hospital Italiano in La Plata. The outbreak subsequently affected over twenty medical centers across Argentina.
In January, a federal court in La Plata identified 159 cases related to this outbreak, comprising 111 fatalities and 48 infections. Legal actions have been initiated against seventeen individuals, including the laboratories’ owner, Ariel García Furfaro, his brother Diego Hernán García, and their mother, Nilda Furfaro, alongside various employees from both laboratories.
Previous Violations
The National Institute of Medicines (Iname) conducted audits that revealed a concerning history of violations before the fentanyl crisis. For instance, in February 2025, the distribution of dopamine was halted due to traceability issues. In April, batches of propofol were recalled amid suspicions of falsification, and cross-contamination was discovered in both diclofenac and morphine products. Inspectors found that at least 69 batches of solutions had been packaged in unauthorized containers, lacking necessary process validations and stability studies.
Communication of Findings
The resolution regarding the revocation of licenses will be communicated to health authorities across all provinces, including the City of Buenos Aires, as well as to the National Institute of Medicines. This extensive communication aims to ensure that all relevant parties are informed of the implications of this decision.
Conclusion
The revocation of licenses for HLB Pharma and Laboratorios Ramallo highlights the critical importance of stringent regulatory oversight in the pharmaceutical industry. This case serves as a stark reminder of the potential consequences when quality control measures fail. Upholding public health standards must remain a priority to prevent similar tragedies in the future.
- Key Takeaways:
- Argentina’s Anmat has revoked licenses for two laboratories linked to fentanyl contamination.
- The contaminated fentanyl resulted in over 100 deaths and multiple infections.
- Historical violations by the laboratories indicated a pattern of negligence in quality control.
- Legal proceedings are underway against several individuals associated with the laboratories.
- Health agencies are being notified to ensure public safety and compliance.
Read more → en.mercopress.com